PeptidePedia The community reference

Prior authorisation (revision 1)

Old revision·09:00, 19 Dec 2024·PBM_Perrin

This is an old revision of this page, as it stood at 09:00, 19 Dec 2024, saved by PBM_Perrin with the summary create article — access and cost stub. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Prior authorisation
Also calledPre-authorisation, pre-approval
Decided byThe payer, not the prescriber
Common criteriaBody-mass index, comorbidity, prior therapy
Topic infobox · conventions

Prior authorisation is a requirement imposed by a payer that a prescription be approved before it will be covered. It is a coverage mechanism rather than a clinical one, and the decision is made by the payer against its own criteria.[1]

For incretin therapies it is close to universal where these drugs are covered at all, and the criteria commonly include a body-mass index threshold, a comorbidity, documented prior attempts at other management, and sometimes a requirement to try a specified alternative first.[1]

References

  1. ^ a b American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).